{'52WeekChange': 0.44558525,
 'SandP52WeekChange': 0.0644362,
 'address1': '1895 Mount Hope Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.14,
 'askSize': 1400,
 'averageDailyVolume10Day': 2975675,
 'averageVolume': 521598,
 'averageVolume10days': 2975675,
 'beta': None,
 'beta3Year': None,
 'bid': 7.01,
 'bidSize': 3100,
 'bookValue': -1.569,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rochester',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.54,
 'dayLow': 7,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.657,
 'enterpriseToRevenue': 323.18,
 'enterpriseValue': 138644064,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '585 271 2765',
 'fiftyDayAverage': 4.4754286,
 'fiftyTwoWeekHigh': 12.23,
 'fiftyTwoWeekLow': 3.22,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 4075557,
 'forwardEps': -2.18,
 'forwardPE': -3.2293577,
 'fromCurrency': None,
 'fullTimeEmployees': 45,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.23393999,
 'heldPercentInstitutions': 0.59376,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vaccinex.com',
 'longBusinessSummary': 'Vaccinex, Inc., a clinical-stage biotechnology '
                        'company, discovers and develops bio therapeutics to '
                        'treat serious diseases and conditions with unmet '
                        'medical needs. The company offers its products for '
                        'the treatment of cancer, neurodegenerative diseases, '
                        'and autoimmune disorders. Its lead product candidate '
                        'is pepinemab that is in clinical development stage '
                        'for the treatment of non-small cell lung cancer '
                        "(NSCLC), Huntington's disease, osteosarcoma, "
                        "melanoma, and Alzheimer's disease. The company is "
                        'also developing VX5, a human antibody to CXCL13 that '
                        'is in preclinical development for the treatment of MS '
                        'and potentially for other autoimmune disorders; and '
                        'VX25, a bi-specific natural killer T (NKT) cell '
                        'stimulator, for the therapeutic application of NKT '
                        'cell stimulation for cancer immunotherapy. It has a '
                        'clinical trial collaboration and supply agreement '
                        'with Merck KGaA to test pepinemab in combination with '
                        'avelumab checkpoint inhibitor in NSCLC patients. '
                        'Vaccinex, Inc. was founded in 2001 and is '
                        'headquartered in Rochester, New York.',
 'longName': 'Vaccinex, Inc.',
 'market': 'us_market',
 'marketCap': 128481408,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_11044719',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -29945000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.54,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '585 271 2700',
 'previousClose': 7.55,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 299.49045,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.54,
 'regularMarketDayLow': 7,
 'regularMarketOpen': 7.54,
 'regularMarketPreviousClose': 7.55,
 'regularMarketPrice': 7.54,
 'regularMarketVolume': 204675,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 18250200,
 'sharesPercentSharesOut': 0.012,
 'sharesShort': 199341,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 208224,
 'shortName': 'Vaccinex, Inc.',
 'shortPercentOfFloat': 0.0301,
 'shortRatio': 3.76,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'VCNX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.137,
 'twoHundredDayAverage': 4.655252,
 'volume': 204675,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vaccinex.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '14620'}